Insmed Incorporated Revenue and Competitors
Estimated Revenue & Valuation
- Insmed Incorporated's estimated annual revenue is currently $173.8M per year.
- Insmed Incorporated received $437.3M in venture funding in January 2018.
- Insmed Incorporated's estimated revenue per employee is $164,692
- Insmed Incorporated's current valuation is $2.8B. (January 2022)
Employee Data
- Insmed Incorporated has 1055 Employees.
- Insmed Incorporated grew their employee count by 29% last year.
Insmed Incorporated's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Executive Assistant to the Chief People Strategy Officer, CIO & Communications Head | Reveal Email/Phone |
3 | Chief Legal Officer | Reveal Email/Phone |
4 | VP Clinical Development Pipeline Programs | Reveal Email/Phone |
5 | Head, Commercial Operations, EMEA | Reveal Email/Phone |
6 | Head, US Market Access | Reveal Email/Phone |
7 | VP and Global Head, Drug Safety and Pharmacovigilance | Reveal Email/Phone |
8 | SVP, Head Clinical Development | Reveal Email/Phone |
9 | Executive Assistant to the Chief Medical Officer | Reveal Email/Phone |
10 | SVP, Head Medical Affairs | Reveal Email/Phone |
Insmed Incorporated Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $8.7M | 56 | 2% | N/A | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $5.7M | 37 | -33% | N/A | N/A |
#4 | $114.8M | 529 | 6% | N/A | N/A |
#5 | $0.8M | 5 | 0% | N/A | N/A |
#6 | $0.6M | 4 | 0% | N/A | N/A |
#7 | $14.7M | 83 | -22% | $206.4M | N/A |
#8 | $492.2M | 1834 | -15% | $568M | N/A |
#9 | $1.9M | 12 | 71% | N/A | N/A |
#10 | $4.8M | 31 | 7% | N/A | N/A |
What Is Insmed Incorporated?
Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company is dedicated to developing and bringing to market therapies that make a real difference in patients lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. Headquartered in Bridgewater, NJ, we are a rapidly growing company with offices in seven countries.
keywords:Biotechnology,Healthcare,Pharmaceuticals
N/A
Total Funding
1055
Number of Employees
$173.8M
Revenue (est)
29%
Employee Growth %
$2.8B
Valuation
N/A
Accelerator
Insmed Incorporated News
Goldman Sachs Group Inc. now owns 463,326 shares of the biopharmaceutical company's stock valued at $12,621,000 after purchasing an additional...
Brokerages expect Insmed Incorporated (NASDAQ:INSM Get Rating) to announce sales of $53.63 million for the current quarter,...
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases.
BRIDGEWATER, N.J., Oct. 28, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 2021 and provided a bu ...
BRIDGEWATER, N.J., May 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from a total of nine posters and oral presentations across its three program ...
Other Companies in Bridgewater
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $307.9M | 1222 | N/A | N/A |
#2 | $446.1M | 1387 | -3% | $1.2B |
#3 | $300M | 1591 | 8% | N/A |
#4 | $276.2M | 1895 | -2% | $68M |
#5 | $749.8M | 2186 | N/A | N/A |
Insmed Incorporated Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2003-07-14 | $12.0M | Private Placement | Wells Fargo Securities | Article |
| 2005-03-16 | $35.0M | Undisclosed | Multiple | Article |
| 2007-05-07 | $18.2M | Undisclosed | CE Unterberg Towbin | Article |
| 2012-10-01 | $26.0M | Undisclosed | Article | |
| 2013-07-18 | $62.4M | Undisclosed | Leerink Swann LLC | Article |
| 2014-08-13 | $80.0M | Undisclosed | Article | |
| 2015-04-01 | $194.0M | Undisclosed | Article | |
| 2015-04-07 | $223.0M | Undisclosed | Citigroup | Article |
| 2017-09-08 | $402.5M | Undisclosed | Goldman Sachs & Co. LLC | Article |
| 2018-01-24 | $300.0M | Undisclosed | Goldman Sachs & Co. LLC | Article |
| 2018-01-25 | $437.3M | Undisclosed | Goldman Sachs & Co. LLC | Article |